Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crenezumab versus placebo in mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease
2015-003034-27Phase 3Terminated
- Sponsor
- Roche
- Start
- May 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Crenezumab with Placebo (2 arms). Primary endpoint: Change from baseline in Clinical Dementia Rating Sum of Boxes. Started May 2016; status: terminated.
02
Drugs
crenezumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2015-003034-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003034-27.